Literature DB >> 27391171

Clinical predictors of Crohn's disease course.

Fernando T Veloso1.   

Abstract

A modern approach to Crohn's disease (CD) should be influenced by the patient's underlying prognosis. Here, I analyse the clinical factors predicting CD course on the basis of information obtained at diagnosis and in the year following diagnosis. Perianal disease at diagnosis appears to be a strong predictor of unfavourable outcome and has been associated with a more frequent use of immunosuppressive treatment. Early age at diagnosis, ileocolonic disease and extraintestinal manifestations are characteristics of patients at risk for more complicated disease. Otherwise, patients subjected to surgery at diagnosis or during the first year of follow-up appear to have a relatively benign outcome. Disease activity in the year after diagnosis appears to be a good predictor of future disease activity as about two-third of the patients who remain in remission tend to remain unchanged thereafter, whereas those patients treated with steroids have, manifestly, an unfavourable subsequent clinical course. Moreover, there is consistent evidence that active smoking is associated with a complicated disease course. The results of the studies reviewed suggest that the combination of 'phenotype at diagnosis' and 'comportment follow-up classification' in the year following diagnosis can be potentially useful prognostic factors in clinical practice. With the development of newer therapies in CD, there is a growing need to predict disease outcome, despite the difficult challenge in anticipating the future clinical course in a given patient.

Entities:  

Mesh:

Year:  2016        PMID: 27391171     DOI: 10.1097/MEG.0000000000000698

Source DB:  PubMed          Journal:  Eur J Gastroenterol Hepatol        ISSN: 0954-691X            Impact factor:   2.566


  4 in total

1.  Comparative Effectiveness of Infliximab Versus Adalimumab in Patients with Biologic-Naïve Crohn's Disease.

Authors:  Amine Benmassaoud; Talal Al-Taweel; Mark Solomon Sasson; Dasha Moza; Matthew Strohl; Uri Kopylov; Laurence Paradis-Surprenant; Mohanad Almaimani; Alain Bitton; Waqqas Afif; Peter L Lakatos; Talat Bessissow
Journal:  Dig Dis Sci       Date:  2017-12-14       Impact factor: 3.199

2.  Risk Factors for Rescue Therapy in Crohn's Patients Maintained on Infliximab After Withdrawal of the Immunomodulator: A Long-Term Follow-Up.

Authors:  Monika Fischer; Sarah C Campbell; Cynthia S J Calley; Debra J Helper; Michael V Chiorean; Hala M Fadda
Journal:  Dig Dis Sci       Date:  2017-10-06       Impact factor: 3.199

3.  Simple pain measures reveal psycho-social pathology in patients with Crohn's disease.

Authors:  Shmuel Odes; Michael Friger; Ruslan Sergienko; Doron Schwartz; Orly Sarid; Vered Slonim-Nevo; Terri Singer; Elena Chernin; Hillel Vardi; Dan Greenberg
Journal:  World J Gastroenterol       Date:  2017-02-14       Impact factor: 5.742

4.  Young age and short duration of the disease are associated with more frequent relapses in inflammatory bowel disease patients.

Authors:  Radislav Nakov; Ventsislav Nakov
Journal:  Med Pharm Rep       Date:  2021-01-29
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.